[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649023":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":42,"responsibleParty":65,"collaborators":26,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":26,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":26,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":91,"whyStopped":26,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Sultan Qaboos University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A (Ketamine)","ACTIVE_COMPARATOR","Nebulised ketamine 1 mg\u002Fkg per dose every 6 hours for 24 hours (4 doses total).",[13],"Drug: Ketamine (1 mg\u002Fkg)",{"label":15,"type":16,"description":17,"interventionNames":18},"Group B (Placebo)","PLACEBO_COMPARATOR","Nebulised 0.9% saline, 3-5 mL per dose, every 6 hours for 24 hours.",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Ketamine (1 mg\u002Fkg)","Group A (Ketamine)\n\n* Nebulised ketamine 1 mg\u002Fkg per dose every 6 hours for 24 hours (4 doses total).\n* Ketamine solution (e.g. 10 mg\u002FmL) diluted with 0.9% saline to a total volume of 3-5 mL.\n\nNebulisation will be delivered via jet nebuliser with oxygen flow 6-8 L\u002Fmin using a mask. A dose will be considered complete when the nebuliser chamber is dry.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","Nebulised 0.9% saline, 3-5 mL per dose, every 6 hours for 24 hours.\n\nNebulisation will be delivered via jet nebuliser with oxygen flow 6-8 L\u002Fmin using a mask. A dose will be considered complete when the nebuliser chamber is dry.",[15],[32],{"name":33,"affiliation":34,"role":35},"Zahraa Ali Al Lawati","College of Medicine and Health Sciences , Sultan Qaboos University","PRINCIPAL_INVESTIGATOR",[37],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},"Zahra Ali Al Lawati","CONTACT","+96892347374","zlawati@squ.edu.om",[43],{"facility":44,"status":26,"city":45,"state":26,"zip":26,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Sultan Qaboos University Hospital","Muscat","Oman","OM",{"type":49,"coordinates":50},"Point",[51,52],58.40778,23.58413,{"lat":52,"lon":51},[55,56,60,62],{"name":33,"role":39,"phone":40,"phoneExt":26,"email":41},{"name":57,"role":39,"phone":58,"phoneExt":26,"email":59},"Raghad Al Abdawani","+96899203929","raghadabdwani@gmail.com",{"name":61,"role":35,"phone":26,"phoneExt":26,"email":26},"Zahraa Al Lawati",{"name":63,"role":64,"phone":26,"phoneExt":26,"email":26},"Raghad Al Abdwani","SUB_INVESTIGATOR",{"type":35,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Dr. Zahraa Al Lawati","Assistant Professor","100649023","phase-2-nebulized-ketamine-for-severe-asthma-attacks-in-children-100649023",false,"NCT07728851","Nebulized Ketamine for Severe Asthma Attacks in Children","Effectiveness and Safety of Nebulized Ketamine in Severe Pediatric Asthma: a Phase-2, Double-blind, Randomized, Placebo-controlled Pilot Trial","Inclusion Criteria:\n\n* Children aged 1 to 13 years.\n* Diagnosis of severe asthma exacerbation (PRAM score 8-12)\n* Prior treatment with standard first-line management (beta-2 agonist, corticosteroid, magnesium sulfate)\n\nExclusion Criteria:\n\n* Known allergy or adverse reaction to ketamine\n* Significant hemodynamic instability\n* Systemic hypertension \\>95th percentile for age\n* Cardiac arrhythmias\n* Congestive heart failure\n* Obstructive sleep apnea with AHI \\>5","ALL","1 Year","13 Years",{"count":79,"type":80},60,"ESTIMATED","INTERVENTIONAL",[83],"PHASE2","This is a double-blinded, randomised, placebo-controlled trial enrolling 60 children aged 1 to 13 years with severe asthma exacerbation. All participants will receive standard therapy. Children not responding to standard therapy will be randomised to intervention arms. Randomization will occur in a 1:1 ratio using a computer-generated Excel sequence with permuted blocks of four, stratified by age (1-5 and 6-13 years). Patients will receive either nebulized ketamine (1 mg\u002Fkg every 6 hours for 24 hours) or 0.9% normal saline placebo. Randomization codes will be maintained by the hospital pharmacy, which will prepare identical numbered packs. During working hours, the pharmacist will dispense the allocated medication; at nights and weekends, pre-prepared packs will be stored securely in the PHDU\u002FPICU under the supervision of the nursing in-charge. Blinding will be maintained for patients, clinicians, and outcome assessors. PRAM scores will be recorded at baseline and at 20, 60, 90, and 120 minutes post-dose. The primary outcome is pediatric respiratory assessment measure (PRAM) score change. Secondary outcomes include need for NIV or intubation and HDU\u002FPICU length of stay.",[86,87],"Asthma Acute","Exacerbation of Allergic Asthma",[89,90],"Asthma","Ketamine","NOT_YET_RECRUITING","2026-07-23",{"date":94,"type":95},"2026-07-27","ACTUAL",{"date":97,"type":80},"2027-01-01",{"date":99,"type":80},"2029-12-31",{"name":5,"class":6},1]